Cargando…

Brd4 Regulates the Homeostasis of CD8(+) T-Lymphocytes and Their Proliferation in Response to Antigen Stimulation

CD8(+) T cells are major components of adaptive immunity and confer robust protective cellular immunity, which requires adequate T-cell numbers, targeted migration, and efficient T-cell proliferation. Altered CD8(+) T-cell homeostasis and impaired proliferation result in dysfunctional immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhilin, Zhang, Yiwen, Ma, Xiancai, Zhou, Mo, Wu, Shiyu, Song, Zheng, Yuan, Yaochang, Chen, Yingshi, Li, Yuzhuang, Wang, Guanwen, Huang, Feng, Qiao, Yidan, Xia, Baijing, Liu, Weiwei, Liu, Jun, Zhang, Xu, He, Xin, Pan, Ting, Xu, Hanshi, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427756/
https://www.ncbi.nlm.nih.gov/pubmed/34512660
http://dx.doi.org/10.3389/fimmu.2021.728082
Descripción
Sumario:CD8(+) T cells are major components of adaptive immunity and confer robust protective cellular immunity, which requires adequate T-cell numbers, targeted migration, and efficient T-cell proliferation. Altered CD8(+) T-cell homeostasis and impaired proliferation result in dysfunctional immune response to infection or tumorigenesis. However, intrinsic factors controlling CD8(+) T-cell homeostasis and immunity remain largely elusive. Here, we demonstrate the prominent role of Brd4 on CD8(+) T cell homeostasis and immune response. By upregulating Myc and GLUT1 expression, Brd4 facilitates glucose uptake and energy production in mitochondria, subsequently supporting naïve CD8(+) T-cell survival. Besides, Brd4 promotes the trafficking of naïve CD8(+) T cells partially through maintaining the expression of homing receptors (CD62L and LFA-1). Furthermore, Brd4 is required for CD8(+) T cell response to antigen stimulation, as Brd4 deficiency leads to a severe defect in clonal expansion and terminal differentiation by decreasing glycolysis. Importantly, as JQ1, a pan-BRD inhibitor, severely dampens CD8(+) T-cell immune response, its usage as an anti-tumor agent or latency-reversing agent for human immunodeficiency virus type I (HIV-1) should be more cautious. Collectively, our study identifies a previously-unexpected role of Brd4 in the metabolic regulation of CD8(+) T cell-mediated immune surveillance and also provides a potential immunomodulation target.